Insmed Incorporated (NASDAQ:INSM) CEO Sells $247,415.31 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 3,771 shares of Insmed stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total transaction of $247,415.31. Following the completion of the sale, the chief executive officer now owns 312,973 shares in the company, valued at approximately $20,534,158.53. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The shares were sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50.
• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total transaction of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50.

Insmed Price Performance

INSM opened at $68.12 on Friday. The stock has a 50-day moving average price of $71.57 and a 200-day moving average price of $73.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market cap of $12.41 billion, a PE ratio of -12.19 and a beta of 0.84. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.06) EPS. Sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insmed

Hedge funds have recently bought and sold shares of the business. Cullen Frost Bankers Inc. raised its position in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP purchased a new position in Insmed in the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed in the 4th quarter worth about $47,000.

Wall Street Analysts Forecast Growth

INSM has been the subject of several recent research reports. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial raised their price objective on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Jefferies Financial Group initiated coverage on Insmed in a research report on Tuesday, May 13th. They set a “buy” rating and a $105.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.